EcoDrugPlus

Proteasome Subunit Beta Type-4-Like

Ensembl ID : ENSOKIG00005012612
Gene Symbol: LOC109875803
3 Cross references
207 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSOKIG00005024141
Gene Symbol: LOC109903588
3 Cross references
165 Possible Orthologues:

Proteasome Subunit Beta Type-7

Ensembl ID : ENSOKIG00005039801
Gene Symbol: LOC109868402
3 Cross references
215 Possible Orthologues:

Proteasome Subunit Beta Type-8

Ensembl ID : ENSOKIG00005022271
Gene Symbol: LOC109903607
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSOKIG00005048281
Gene Symbol: LOC109907528
3 Cross references
212 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSOKIG00005048222
Gene Symbol: LOC109907524
3 Cross references
200 Possible Orthologues:

Protein Lbh

Ensembl ID : ENSOKIG00005016303
Gene Symbol: LOC109894394
2 Cross references
177 Possible Orthologues:

Protein Arginine N-Methyltransferase 5

Ensembl ID : ENSOKIG00005038649
Gene Symbol: LOC109882578
3 Cross references
192 Possible Orthologues:

Protein Arginine N-Methyltransferase 5-Like

Ensembl ID : ENSOKIG00005050797
Gene Symbol: LOC109871938
3 Cross references
192 Possible Orthologues:

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha

Ensembl ID : ENSOKIG00005021976
Gene Symbol: LOC109864868
3 Cross references
215 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSOKIG00005047733
Gene Symbol: PRKCA
3 Cross references
207 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSOKIG00005019679
Gene Symbol: PRKCA
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).